NASDAQ:MLNT - Melinta Therapeutics Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0 (0.00%)
Get New Melinta Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MLNT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MLNT

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Melinta Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for MLNT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Melinta Therapeutics. This rating has held steady since October 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/11/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/11/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/10/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/5/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/25/2019HC WainwrightReiterated RatingHoldHigh
8/12/2019HC WainwrightDowngradeBuy ➝ NeutralMedium
7/18/2019HC WainwrightReiterated RatingBuy$13.00High
6/20/2019GabelliReiterated RatingSellLow
6/20/2019HC WainwrightReiterated RatingBuy ➝ Buy$45.00 ➝ $13.00High
6/20/2019WBB SecuritiesDowngradeSpeculative Buy ➝ HoldHigh
6/19/2019Cantor FitzgeraldSet Price TargetBuy$15.00Low
6/14/2019JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightHigh
5/10/2019GabelliDowngradeHold ➝ SellHigh
5/10/2019Jefferies Financial GroupDowngradeBuy ➝ Hold$14.00 ➝ $5.00High
5/9/2019Cantor FitzgeraldReiterated RatingBuy$15.00High
12/20/2018GabelliDowngradeBuy ➝ HoldHigh
12/18/2018LADENBURG THALM/SH SHReiterated RatingBuy ➝ Buy$70.00High
10/22/2018HC WainwrightLower Price TargetBuy ➝ Buy$70.00 ➝ $60.00High
10/22/2018GabelliUpgradeHold ➝ Buy$57.50High
10/2/2018HC WainwrightReiterated RatingBuy$70.00Medium
9/24/2018HC WainwrightReiterated RatingBuy$70.00Low
9/18/2018Cantor FitzgeraldSet Price TargetBuy$75.00High
9/11/2018HC WainwrightInitiated CoverageBuy$70.00High
9/11/2018Jefferies Financial GroupInitiated CoverageBuy$75.00High
8/3/2018Cantor FitzgeraldReiterated RatingBuy$75.00Low
7/2/2018Cantor FitzgeraldReiterated RatingOverweightMedium
7/1/2018Cantor FitzgeraldInitiated CoverageBuy$75.00Medium
5/25/2018WBB SecuritiesUpgradeHold ➝ Buy$40.00High
5/9/2018Robert W. BairdUpgradeNeutral ➝ OutperformHigh
11/30/2017GabelliUpgradeSell ➝ HoldHigh
11/30/2017LADENBURG THALM/SH SHUpgradeNeutral ➝ BuyHigh
11/1/2017Robert W. BairdUpgradeUnderperform ➝ Neutral$10.00N/A
10/26/2017Jefferies Financial GroupReiterated RatingHold ➝ NeutralN/A
9/14/2017Jefferies Financial GroupReiterated RatingHold$15.00Medium
8/10/2017Roth CapitalDowngradeBuy ➝ Neutral$40.00 ➝ $20.00High
8/10/2017Stifel NicolausReiterated RatingHold$20.00High
(Data available from 7/5/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/7/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/6/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/5/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/7/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/6/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/6/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/5/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/5/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Melinta Therapeutics logo
Melinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens. The company has license agreements with Yale University, Medical Research Council, Wakunaga Pharmaceutical Co., Ltd., and CyDex Pharmaceuticals, Inc. Melinta Therapeutics, Inc. was founded in 2000 and is headquartered in New Haven, Connecticut.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.48
Low: $0.35
High: $0.50

52 Week Range

Now: N/A

Volume

N/A

Average Volume

713,628 shs

Market Capitalization

$6.88 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

4.16

Frequently Asked Questions

What sell-side analysts currently cover shares of Melinta Therapeutics?

The following Wall Street sell-side analysts have issued reports on Melinta Therapeutics in the last year:
View the latest analyst ratings for MLNT.

What is the current price target for Melinta Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Melinta Therapeutics in the last year.
View the latest price targets for MLNT.

What is the current consensus analyst rating for Melinta Therapeutics?

Melinta Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for MLNT.

How do I contact Melinta Therapeutics' investor relations team?

Melinta Therapeutics' physical mailing address is 44 WHIPPANY ROAD, MORRISTOWN NJ, 07960. The biotechnology company's listed phone number is 908-617-1309 and its investor relations email address is [email protected] The official website for Melinta Therapeutics is www.melinta.com. Learn More about contacing Melinta Therapeutics investor relations.